Home » Topics » BioWorld Science

BioWorld Science
RSS

Biogen exercises option to license preclinical ASO for spinal muscular atrophy

Jan. 5, 2022

Discovery of novel selective and orally bioavailable AR-V7 degrader

Jan. 5, 2022

Merck & Co. synthesizes RIPK1 inhibitors

Jan. 5, 2022

Vertex Pharmaceuticals identifies new APOL1 inhibitors

Jan. 5, 2022

Novartis presents new Cav1.2 activators

Jan. 5, 2022

Incyte divulges new ACVR1 inhibitors

Jan. 5, 2022

MCUF-651, a GC-A PAM for the treatment of cardiovascular, renal and metabolic diseases

Jan. 5, 2022

Amgen discloses new SCN9A blockers

Jan. 5, 2022

Activation of ATF4 is required for DLBCL growth

Jan. 5, 2022

OR5B21 is associated with breast cancer metastasis

Jan. 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...